FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer.
- Author:
Hong Suk SONG
1
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. shs7436@dsmc.or.kr
- Publication Type:Editorial
- Keywords:
Stomach neoplasm;
Chemotherapy;
Oxaliplatin
- MeSH:
Aged;
Antineoplastic Combined Chemotherapy Protocols;
Drug Therapy, Combination;
Fluorouracil;
Humans;
Leucovorin;
Organoplatinum Compounds;
Stomach Neoplasms
- From:Korean Journal of Medicine
2012;82(1):35-36
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The FOLFOX-4 regimen as first-line treatment in patients with advanced gastric cancer has not evidence of category 1 for prolongation of survival in patients with advanced gastric cancer. Therefore, the use is preferred in the second line. But, especially in elderly patients, FOLFOX regimen was active and well tolerated with lower toxicities. Further phase III study is warranted to evaluate the evidence for prolongation of survival in elderly patients or combination therapy with target agents in advanced gastric cancer.
